Idera Pharmaceuticals Inc. (IDRA) announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection or HCV.
IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.
The company said that, in this 4-week trial, IMO-2125 was well tolerated and induced dose-dependent increases in endogenous interferon-alpha and other cytokines. Also, IMO-2125 demonstrated a treatment-related decrease in viral load at escalating dose levels.
Based on these data, the company noted that it is extending the trial to a fifth dose level and beginning to recruit patients in this cohort. Idera Pharma intends to use the ongoing clinical trial results to guide its strategy for further development of IMO-2125 for the null responder HCV patient population.
For comments and feedback: editorial@rttnews.com